牛牛AI助理已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will present at the TD Cowen 44th Annual Health Care Conference in Boston, MA, from March 4-6, 2024. The presentation, which will focus on Cybin's mission to revolutionize mental healthcare with psychedelic-based therapeutics, is scheduled for a live webcast on March 4, 2024, at 12:50 p.m. ET. Cybin is developing treatments for mental health conditions, including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, and is supported by a network of partners and scientists. The company, founded in 2019, operates in Canada, the US, the UK, the Netherlands, and Ireland.
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will present at the TD Cowen 44th Annual Health Care Conference in Boston, MA, from March 4-6, 2024. The presentation, which will focus on Cybin's mission to revolutionize mental healthcare with psychedelic-based therapeutics, is scheduled for a live webcast on March 4, 2024, at 12:50 p.m. ET. Cybin is developing treatments for mental health conditions, including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, and is supported by a network of partners and scientists. The company, founded in 2019, operates in Canada, the US, the UK, the Netherlands, and Ireland.
臨床階段的生物製藥公司Cybin Inc. 宣佈，其首席執行官道格·德賴斯代爾將於2024年3月4日至6日出席在馬薩諸塞州波士頓舉行的TD Cowen第44屆年度醫療保健會議。該演講定於美國東部時間2024年3月4日下午 12:50 進行網絡直播，重點介紹Cybin的使命，即通過迷幻藥療法徹底改變心理保健。Cybin 正在開發心理健康狀況的治療方法，包括用於重度抑鬱症的 CYB003 和用於廣泛性焦慮症的 CYB004，並得到了合作伙伴和科學家網絡的支持。該公司成立於2019年，在加拿大、美國、英國、荷蘭和愛爾蘭開展業務。
臨床階段的生物製藥公司Cybin Inc. 宣佈，其首席執行官道格·德賴斯代爾將於2024年3月4日至6日出席在馬薩諸塞州波士頓舉行的TD Cowen第44屆年度醫療保健會議。該演講定於美國東部時間2024年3月4日下午 12:50 進行網絡直播，重點介紹Cybin的使命，即通過迷幻藥療法徹底改變心理保健。Cybin 正在開發心理健康狀況的治療方法，包括用於重度抑鬱症的 CYB003 和用於廣泛性焦慮症的 CYB004，並得到了合作伙伴和科學家網絡的支持。該公司成立於2019年，在加拿大、美國、英國、荷蘭和愛爾蘭開展業務。
有用
沒用